Whilst TRPC4 activation was shown to modulate insulin secretion, and TRPC1/TRPC5 signalling was suggested to regulate adiponectin release by adipocytes [34,35], TRPC4/TRPC5 inhibitors were recently patented for use in weight loss, type II diabetes, MS, and hepatic steatosis (accession numbers: WO/2018/146485; EP3579838; US20200345741). Here, ADIPOQ is linked to Hepatic steatosis.